US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

10.84

-2.2400-17.13%

Pre-market: 11.070.2300+2.12%07:00 EDT

Volume:3.99M

Turnover:44.16M

Market Cap:393.41M

PE:-4.15

High:12.10

Open:11.90

Low:10.30

Close:13.08

52wk High:33.20

52wk Low:10.30

Shares:36.29M

Float Shares:19.98M

Volume Ratio:7.31

T/O Rate:19.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:1.42

PE(LYR):-0.97

Loading ...

Overview Company News Filings

Evommune Initiates Phase 2B Clinical Trial of Mrgprx2 Inhibitor Evo756 in Migraine Prophylaxis

THOMSON REUTERS

Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260

Independent Director of Evommune Arthur Kirsch Buys More Stock

Simply Wall St.

Evommune Director Arthur S. Kirsch Reports Purchase of $133,000 in Common Shares

Evommune Publishes Corporate Deck Outlining Chronic Inflammation Drug Pipeline, Led by Evo756 and Evo301 Programs

Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)

Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study

Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market

Evommune is Maintained at Overweight by Morgan Stanley

HC Wainwright Downgrades Evommune to Neutral From Buy

MT Newswires Live

U.S. Research Roundup- Comcast, Honeywell Aerospace, Qualys

Evommune price target lowered to $28 from $53 at Clear Street

Evommune Halts Urticaria Drug Development After Phase 2b Trial Fails Primary Goal, Shifts Focus to Dermatitis and Migraine

Top Midday Decliners

MT Newswires Live

Evommune Cut to Market Perform from Outperform by William Blair

Evommune Inc : Leerink Partners Cuts Target Price to $28 from $52

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)

Evommune Sinks as Skin Disease Drug Fails Mid-stage Trial

Evommune downgraded to Market Perform from Outperform at William Blair

Evommune Publishes Migraine Presentation on Mrgprx2 Antagonism

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/EVMN/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":10.84,"timestamp":1788984000000,"preClose":13.08,"halted":0,"volume":3986472,"hourTrading":{"tag":"盘前","latestPrice":11.07,"preClose":10.84,"latestTime":"07:00 EDT","volume":15,"amount":163.399995,"timestamp":1789038000232,"change":0.23,"changeRate":0.021218,"amplitude":0.048893},"delay":0,"changeRate":-0.17125382262996944,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Pre-Mkt","change":-2.24,"latestTime":"09-10 08:22:42 EDT","open":11.9,"high":12.1,"low":10.3001,"amount":44160677.767248,"amplitude":0.137607,"askPrice":12.02,"askSize":100,"bidPrice":10,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-2.609,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":10.84,"preHourTrading":{"tag":"盘前","latestPrice":11.07,"preClose":10.84,"latestTime":"07:00 EDT","volume":15,"amount":163.399995,"timestamp":1789038000232,"change":0.23,"changeRate":0.021218,"amplitude":0.048893},"postHourTrading":{"tag":"盘后","latestPrice":11.07,"preClose":10.84,"latestTime":"19:30 EDT","volume":478,"amount":5246.536,"timestamp":1788996605827,"change":0.23,"changeRate":0.021218,"amplitude":0.021218},"volumeRatio":7.30613631790136,"impliedVol":0.7207,"impliedVolPercentile":0.1875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":7.30613631790136,"shares":36292113,"dividePrice":0,"high":12.1,"amplitude":0.137607,"preClose":13.08,"low":10.3001,"week52Low":10.3001,"pbRate":"1.42","psRate":"39.34","week52High":33.2,"institutionHeld":0,"latestPrice":10.84,"committee":-0.941748,"eps":-2.609,"divideRate":0,"volume":3986472,"delay":0,"ttmEps":-2.609,"open":11.9,"prevYearClose":17.12,"prevWeekClose":12.27,"prevMonthClose":12.66,"prevQuarterClose":13.29,"fiveDayClose":12.48,"twentyDayClose":14.21,"sixtyDayClose":19.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5833,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1787803200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-09-09","current":-4.154849,"percent":0.976303,"low":-16.229076,"twenty":-12.375007,"median":-9.705573,"eighty":-6.223712,"high":-4.600344,"avg":-9.709,"sd":2.933137,"marketCap":474700838},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973},{"date":"2026-08-28","current":-5.16772,"twenty":-12.413708,"median":-9.712404,"eighty":-6.987812,"marketCap":489217683},{"date":"2026-09-04","current":-4.600344,"twenty":-12.384421,"median":-9.710846,"eighty":-6.276801,"marketCap":435505356},{"date":"2026-09-09","current":-5.014375,"twenty":-12.375007,"median":-9.705573,"eighty":-6.223712,"marketCap":474700838}],"updateTime":1789042962549},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655387476","title":"Evommune Initiates Phase 2B Clinical Trial of Mrgprx2 Inhibitor Evo756 in Migraine Prophylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2655387476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655387476?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA8LHQNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650158610","title":"Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260","url":"https://stock-news.laohu8.com/highlight/detail?id=2650158610","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650158610?lang=en_us&edition=fundamental","pubTime":"2026-07-11 08:00","pubTimestamp":1783728046,"startTime":"0","endTime":"0","summary":"Evommune CFO Kyle Carver acquires 1,000 common shares for $13,260Evommune CFO Kyle Carver bought 1,000 common shares at USD 13.26.Direct holdings rose to 60,335 shares.Disclaimer:This news brief was c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260711:nNDL4JpcFl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650110138","title":"Independent Director of Evommune Arthur Kirsch Buys More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2650110138","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650110138?lang=en_us&edition=fundamental","pubTime":"2026-07-10 19:35","pubTimestamp":1783683354,"startTime":"0","endTime":"0","summary":"Investors who take an interest in Evommune, Inc. ( NYSE:EVMN ) should definitely note that the Independent Director...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-evmn/evommune/news/independent-director-of-evommune-arthur-kirsch-buys-more-sto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-evmn/evommune/news/independent-director-of-evommune-arthur-kirsch-buys-more-sto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650691432","title":"Evommune Director Arthur S. Kirsch Reports Purchase of $133,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650691432","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650691432?lang=en_us&edition=fundamental","pubTime":"2026-07-09 08:00","pubTimestamp":1783555257,"startTime":"0","endTime":"0","summary":"Evommune director Arthur S. Kirsch reports purchase of $133,000 in common sharesEvommune director Arthur S. Kirsch bought 10,000 common shares at USD 13.3, raising beneficial ownership to 10,000 share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL4D2tWD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Evommune Director Arthur S. Kirsch Reports Purchase of $133,000 in Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649675371","title":"Evommune Publishes Corporate Deck Outlining Chronic Inflammation Drug Pipeline, Led by Evo756 and Evo301 Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2649675371","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649675371?lang=en_us&edition=fundamental","pubTime":"2026-07-07 01:32","pubTimestamp":1783359122,"startTime":"0","endTime":"0","summary":"Evommune publishes corporate deck outlining chronic inflammation drug pipeline, led by EVO756 and EVO301 programsEvommune highlighted two Phase 2 inflammation assets, led by oral MRGPRX2 antagonist EV","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL9Rh4JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649645924","title":"Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649645924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649645924?lang=en_us&edition=fundamental","pubTime":"2026-07-06 13:55","pubTimestamp":1783317335,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Evommune, Inc., with a price target of $54.00. Thomps...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648654790","title":"Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2648654790","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648654790?lang=en_us&edition=fundamental","pubTime":"2026-07-02 00:31","pubTimestamp":1782923460,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ($EVMN) announced an update on their ongoing clinical study. The Phase 2 study “A Randomized, Double-Blind, Placebo Controlled Study...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-migraine-trial-what-investors-should-know-about-this-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-migraine-trial-what-investors-should-know-about-this-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EVMN","BK4211","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648547135","title":"Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2648547135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648547135?lang=en_us&edition=fundamental","pubTime":"2026-07-02 00:30","pubTimestamp":1782923439,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ($EVMN) announced an update on their ongoing clinical study. Evommune, Inc. has completed a Phase 2b trial of EVO756 in adults with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-trial-completion-signals-key-milestone-in-chronic-urticaria-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-trial-completion-signals-key-milestone-in-chronic-urticaria-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647591635","title":"Evommune is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2647591635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647591635?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:06","pubTimestamp":1782824760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings(END) Dow Jones NewswiresJune 30, 2026 09:06 ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647300545","title":"HC Wainwright Downgrades Evommune to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2647300545","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647300545?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:14","pubTimestamp":1782818047,"startTime":"0","endTime":"0","summary":"HC Wainwright Downgrades Evommune to Neutral From Buy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647533196","title":"U.S. Research Roundup- Comcast, Honeywell Aerospace, Qualys","url":"https://stock-news.laohu8.com/highlight/detail?id=2647533196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647533196?lang=en_us&edition=fundamental","pubTime":"2026-06-30 15:51","pubTimestamp":1782805890,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Comcast, Honeywell Aerospace, QualysJune 30 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Comcast","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nL8N4320EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FUL","CMCSA","GOU","HRMY","AVAV","BKU","HWKN","CE","CNXC","ABVX","CNR","EVMN","CHTR","AIR","GOOP","AMDG","GOOX","EOG","DOW","FOXF","AMDU","GOOY","AMYY","DIS","AMD","BROS","AMDD","EVRG","FCBC","HON","BAC","EVH","AADX","AA","AMDS","AMDY","EXPE","GOOW","AMDL","BKNG","GSX","DAL","GNRC","ASTH","TECH","AAL","GOOGL","FBIN","CELH","HONA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647302943","title":"Evommune price target lowered to $28 from $53 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2647302943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647302943?lang=en_us&edition=fundamental","pubTime":"2026-06-30 04:20","pubTimestamp":1782764455,"startTime":"0","endTime":"0","summary":"Clear Street lowered the firm’s price target on Evommune (EVMN) to $28 from $53 and keeps a Buy rating on the shares after the company announced th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-28-from-53-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-28-from-53-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151653547","title":"Evommune Halts Urticaria Drug Development After Phase 2b Trial Fails Primary Goal, Shifts Focus to Dermatitis and Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=1151653547","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151653547?lang=en_us&edition=fundamental","pubTime":"2026-06-30 03:50","pubTimestamp":1782762639,"startTime":"0","endTime":"0","summary":"The biotechnology firm Evommune announced top-line results from a Phase 2b clinical trial of EVO756 for moderate-to-severe chronic spontaneous urticaria on Monday, revealing the study did not meet...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647309875","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2647309875","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647309875?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:49","pubTimestamp":1782755397,"startTime":"0","endTime":"0","summary":"Evommune's  top-line results from a phase 2b trial of EVO756 to treat adults with moderate-to-severe chronic spontaneous urticaria failed to meet the primary endpoint at any dosage, according to a statement released Monday.Shares sank 39% as intraday trading volume surged to over 5.9 million from a daily average of about 415,000.Solidion Technology  said Monday it plans to opportunistically acquire shares of SpaceX  as a long-term strategic treasury asset, using a modest portion of its cash reserves.Shares of Solidion slumped 20%, with intraday trading volume climbing to about 2.4 million from a daily average of roughly 2.8 million.Martin Marietta Materials  agreed to combine with limestone supplier Lhoist North America in a $13.5 billion deal.Shares dropped 6.6% as intraday trading volume rose to more than 759,300 from a daily average of about 509,000.Price: 15.35, Change: -9.83, Percent Change: -39.04","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLM.AU","LU0300736492.USD","SPAL","SPCQ","LU0300736062.USD","ES3.SI","G3B.SI","BK7095","LU2237438978.USD","BK4096","BK4585","SPAX","SPCU","BK4089","SSPC","BK4139","SPCM","BK4548","SG9999001077.SGD","SPCG","LOFF","LU0053666078.USD","BK4588","EVMN","SPCF","GAB.SI","SNK","STI","SPCH","MLM","BK4011","SPCX","STI.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647306334","title":"Evommune Cut to Market Perform from Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2647306334","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647306334?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:01","pubTimestamp":1782752460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 13:01 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647370102","title":"Evommune Inc : Leerink Partners Cuts Target Price to $28 from $52","url":"https://stock-news.laohu8.com/highlight/detail?id=2647370102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647370102?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:35","pubTimestamp":1782743711,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN4310V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647670377","title":"Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647670377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647670377?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:50","pubTimestamp":1782741008,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH) with neutral ratings, indicating that the exper...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-and-theravance-biopharma-tbph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-and-theravance-biopharma-tbph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4139","HCSG","LU0128526141.USD","BK4581","TBPH","LABU","EVMN","BK4588","BK4007","BK4137","BK4585","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372007","title":"Evommune Sinks as Skin Disease Drug Fails Mid-stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372007?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:47","pubTimestamp":1782740844,"startTime":"0","endTime":"0","summary":"BUZZ-Evommune sinks as skin disease drug fails mid-stage trial** Shares of drug developer EvommuneEVMN.Nfall 32% to over four-month low of $17.10** Co says its experimental pill, EVO756, did not reduce hive activity scores significantly better than a placebo after 12 weeks, failing to meet the main goal of a mid-stage trial** Co was testing the drug in patients with moderate-to-severe chronic spontaneous urticaria, commonly known as chronic hives, which causes recurring itchy welts on the skin that can last for months or years and significantly disrupt daily life** RBC Capital Markets analysts cut Evommune's PT to $30 from $50 and said the research firm believes \"the issue is more likely the indication rather than the drug or mechanism\"** EVO756 works by blocking the MRGPRX2 receptor on mast cells, a pathway involved in triggering inflammation and itch** The trial enrolled 160 patients who had not responded to standard antihistamines** Co says it plans to continue development of EVO756","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL4N43114C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377951","title":"Evommune downgraded to Market Perform from Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377951","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647377951?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:40","pubTimestamp":1782740441,"startTime":"0","endTime":"0","summary":"William Blair downgraded Evommune (EVMN) to Market Perform from Outperform without a price target after the company announced that the Phase IIb st...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-downgraded-to-market-perform-from-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-downgraded-to-market-perform-from-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372957","title":"Evommune Publishes Migraine Presentation on Mrgprx2 Antagonism","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372957","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372957?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:25","pubTimestamp":1782739518,"startTime":"0","endTime":"0","summary":"Evommune publishes migraine presentation on MRGPRX2 antagonismEvommune published a medical research presentation outlining MRGPRX2 antagonism as a potential migraine approach targeting meningeal mast ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL83sMQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":106,"code":"91000000","status":"200"}]}}